



December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-002306-31/ Novartis Protocol ID CLCZ696A2320E1

An open-label, long term (52 week) extension study to evaluate the safety, tolerability, and efficacy of treatment with LCZ696 monotherapy and LCZ696 in combination with amlodipine in patients with essential hypertension

Trial CLCZ696A2320E1 was cancelled with no patient enrollment and as such, no results will be reported.